- Home
- DARE vs WVVI Comparison
DARE vs WVVI Comparison
Compare DARE & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- WVVI
- Stock Information
- Founded
- DARE 2015
- WVVI 1983
- Country
- DARE United States
- WVVI United States
- Employees
- DARE N/A
- WVVI N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- WVVI Beverages (Production/Distribution)
- Sector
- DARE Health Care
- WVVI Consumer Staples
- Exchange
- DARE Nasdaq
- WVVI Nasdaq
- Market Cap
- DARE 26.3M
- WVVI 28.2M
- IPO Year
- DARE N/A
- WVVI N/A
- Fundamental
- Price
- DARE $2.40
- WVVI $5.53
- Analyst Decision
- DARE Strong Buy
- WVVI
- Analyst Count
- DARE 3
- WVVI 0
- Target Price
- DARE $12.50
- WVVI N/A
- AVG Volume (30 Days)
- DARE 39.6K
- WVVI 24.7K
- Earning Date
- DARE 08-11-2025
- WVVI 08-12-2025
- Dividend Yield
- DARE N/A
- WVVI N/A
- EPS Growth
- DARE N/A
- WVVI N/A
- EPS
- DARE N/A
- WVVI N/A
- Revenue
- DARE $25,909.00
- WVVI $38,520,945.00
- Revenue This Year
- DARE $99,756.91
- WVVI N/A
- Revenue Next Year
- DARE $119.77
- WVVI N/A
- P/E Ratio
- DARE N/A
- WVVI N/A
- Revenue Growth
- DARE N/A
- WVVI N/A
- 52 Week Low
- DARE $2.35
- WVVI $3.17
- 52 Week High
- DARE $4.60
- WVVI $7.18
- Technical
- Relative Strength Index (RSI)
- DARE 30.40
- WVVI 48.00
- Support Level
- DARE $2.37
- WVVI $5.50
- Resistance Level
- DARE $2.54
- WVVI $5.86
- Average True Range (ATR)
- DARE 0.11
- WVVI 0.54
- MACD
- DARE -0.04
- WVVI 0.04
- Stochastic Oscillator
- DARE 8.20
- WVVI 38.43
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About WVVI Willamette Valley Vineyards Inc.
Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.